Delayed-release dimethyl fumarate ( DMF , also known as gastro-resistant DMF ) , demonstrated efficacy and safety in relapsing-remitting multiple sclerosis in the 2-year , randomized , placebo-controlled , phase 3 DEFINE and CONFIRM trials .